Hypertriglyceridemia

3,620views

Hypertriglyceridemia

G3n3tics to add

G3n3tics to add

Legg-Calve-Perthes disease
1p36 deletion syndrome: Year of the Zebra
Cleidocranial dysplasia
Developmental dysplasia of the hip: Clinical sciences
Collagen disorders: Pathology review
Approach to connective tissue disorders: Clinical sciences
Fetal alcohol syndrome
Rett syndrome
Approach to a child with Down syndrome (trisomy 21): Clinical sciences
Approach to aneuploidies and microdeletions: Clinical sciences
Approach to inborn errors of metabolism (acute): Clinical sciences
Approach to inborn errors of metabolism (progressive or chronic): Clinical sciences
Approach to neurocutaneous syndromes: Clinical sciences
Approach to prenatal teratogen exposure: Clinical sciences
Approach to primary immunodeficiencies: Clinical sciences
Cystic fibrosis and primary ciliary dyskinesia: Clinical sciences
Sickle cell disease: Clinical sciences
Developmental milestones (newborn and infant): Clinical sciences
Developmental milestones (toddler): Clinical sciences
Developmental milestones (childhood): Clinical sciences
Approach to atypical genitalia: Clinical sciences
Approach to delay or regression in developmental milestones: Clinical sciences
Approach to delayed puberty: Clinical sciences
Approach to feeding and eating disorders: Clinical sciences
Approach to growth faltering: Clinical sciences
Approach to hypotonia (newborn and infant): Clinical sciences
Approach to neurodevelopmental disorders: Clinical sciences
Approach to poor feeding (newborn and infant): Clinical sciences
Approach to precocious puberty: Clinical sciences
Approach to primary amenorrhea: Clinical sciences
Approach to short stature: Clinical sciences
Obesity (pediatrics): Clinical sciences
Congenital cytomegalovirus (NORD)
Chiari malformation
Seizures and epilepsy
Approach to epilepsy: Clinical sciences
Febrile seizure (pediatrics): Clinical sciences
Early infantile epileptic encephalopathy (NORD)
Spinocerebellar ataxia (NORD)
Sturge-Weber syndrome
Spina bifida
Von Hippel-Lindau disease: Year of the Zebra 2024
Neurocutaneous disorders: Pathology review
Human development days 1-4
Human development days 4-7
Human development week 2
Human development week 3
Development of the digestive system and body cavities
Development of the fetal membranes
Development of the placenta
Development of the umbilical cord
Development of twins
Hedgehog signaling pathway
Ectoderm
Endoderm
Mesoderm
Development of the cardiovascular system
Fetal circulation
Development of the eye
Development of the gastrointestinal system
Development of the teeth
Development of the tongue
Development of the axial skeleton
Development of the limbs
Development of the muscular system
Development of the renal system
Development of the reproductive system
Development of the respiratory system
Peutz-Jeghers syndrome
Autism spectrum disorder
Autism spectrum disorder: Clinical sciences
Developmental and learning disorders: Pathology review
Learning disability
von Hippel-Lindau disease
Muscular dystrophies and mitochondrial myopathies: Pathology review
Fatty acid oxidation
Fatty acid synthesis
Classical homocystinuria (NORD)
Homocystinuria
Alkaptonuria
Cystinuria (NORD)
Hartnup disease
Maple syrup urine disease
Ornithine transcarbamylase deficiency
Phenylketonuria (NORD)
Essential fructosuria
Galactosemia
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hereditary fructose intolerance
Lactose intolerance
Pyruvate dehydrogenase deficiency
Abetalipoproteinemia
Familial hypercholesterolemia
Hyperlipidemia
Hypertriglyceridemia
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glycogen storage disease type III
Glycogen storage disease type IV
Glycogen storage disease type V
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Fabry disease (NORD)
Gaucher disease (NORD)
Krabbe disease
Leukodystrophy
Metachromatic leukodystrophy (NORD)
Niemann-Pick disease type C
Niemann-Pick disease types A and B (NORD)
Tay-Sachs disease (NORD)
Cystinosis
Disorders of amino acid metabolism: Pathology review
Disorders of carbohydrate metabolism: Pathology review
Disorders of fatty acid metabolism: Pathology review
Dyslipidemias: Pathology review
Glycogen storage disorders: Pathology review
Lysosomal storage disorders: Pathology review
Hypothyroidism: Pathology review
Hypothyroidism
Approach to hypothyroidism: Clinical sciences
Hypothyroidism medications
Hyperthyroidism medications
Approach to hyperthyroidism and thyrotoxicosis: Clinical sciences
Hyperthyroidism
Hyperthyroidism: Pathology review
Hashimoto thyroiditis: Clinical sciences
Thyroid nodules: Clinical sciences
Multiple endocrine neoplasia: Pathology review
Disorders of sex chromosomes: Pathology review
Disorders of sexual development and sex hormones: Pathology review
Hypopituitarism: Pathology review
Growth hormone deficiency
Congenital adrenal hyperplasia
Atrial septal defect
Coarctation of the aorta
Patent ductus arteriosus
Ventricular septal defect
Hypoplastic left heart syndrome
Tetralogy of Fallot
Total anomalous pulmonary venous return
Transposition of the great vessels
Persistent truncus arteriosus
Cyanotic congenital heart defects: Pathology review
Acyanotic congenital heart defects: Pathology review
Congenital renal disorders: Pathology review
Congenital gastrointestinal disorders: Pathology review
Congenital neurological disorders: Pathology review
Congenital TORCH infections: Pathology review
Approach to congenital heart diseases (cyanotic): Clinical sciences
Approach to congenital heart diseases (acyanotic): Clinical sciences
Introduction to the immune system
MHC class I and MHC class II molecules
VDJ rearrangement
Antibody classes
Ataxia-telangiectasia
DiGeorge syndrome
Wiskott-Aldrich syndrome
X-linked agammaglobulinemia
Selective immunoglobulin A deficiency
Isolated primary immunoglobulin M deficiency
Adenosine deaminase deficiency
Hyper IgM syndrome
Complement deficiency
Chronic granulomatous disease
Leukocyte adhesion deficiency
Thymic aplasia
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Cornelia de Lange syndrome: Year of the Zebra
Alagille syndrome (NORD): Year of the Zebra
Alkaptonuria: Year of the Zebra
Alpha-1 antitrypsin deficiency: Year of the Zebra 2024
Chopra-Amiel-Gordon syndrome: Year of the Zebra 2024
FOXG1 syndrome: Year of the Zebra
Gaucher disease (NORD): Year of the Zebra
Gorlin syndrome: Year of the Zebra
Leprosy: Year of the Zebra
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: Year of the Zebra
Nail-patella syndrome: Year of the Zebra
PGAP3-congenital disorder of glycosylation: Year of the Zebra
Phenylketonuria (NORD): Year of the Zebra
Pierre Robin sequence: Year of the Zebra
Retroperitoneal fibrosis: Year of the Zebra
Sanfilippo syndrome: Year of the Zebra
Shwachman-Diamond syndrome: Year of the Zebra
Turner syndrome: Year of the Zebra
Andersen-Tawil syndrome: Year of the Zebra 2025
Peroxisomal disorders: Pathology review
Cytoskeleton and elastin disorders: Pathology review
Epidermolysis bullosa: Year of the Zebra
Gorlin syndrome (Gorlin Syndrome Alliance)
Antepartum care (first trimester): Clinical sciences
Antepartum care (second trimester): Clinical sciences
Antepartum care (third trimester): Clinical sciences
Fetal aneuploidy screening: Clinical sciences
Intrapartum care (1st, 2nd, 3rd, and 4th stages): Clinical sciences
Cystic fibrosis: Pathology review
Autosomal trisomies: Pathology review
Miscellaneous genetic disorders: Pathology review
Gastroschisis
Omphalocele
Approach to abdominal wall defects: Clinical sciences
Early pregnancy loss: Clinical sciences
Pyloric stenosis: Clinical sciences
Pyloric stenosis
Esophageal atresia and tracheoesophageal fistula: Year of the Zebra
Intestinal atresia
Hirschsprung disease
Hirschsprung disease: Year of the Zebra
Alagille syndrome (NORD)
Renal agenesis
Bladder exstrophy
Horseshoe kidney
Hypospadias and epispadias
Potter sequence
Posterior urethral valves
Renal tubular acidosis
Parathyroid disorders and calcium imbalance: Pathology review
Diabetes insipidus
Diabetes insipidus: Clinical sciences
Breast cancer: Pathology review
Breast cancer
Breast cancer screening: Clinical sciences
Colorectal polyps and cancer: Pathology review
Neuroendocrine tumors of the gastrointestinal system: Pathology review
Familial adenomatous polyposis
Multiple endocrine neoplasia: Clinical sciences
Fanconi anemia: Year of the Zebra 2025
Desmoid Tumor (NORD)
Multiple endocrine neoplasia
Oncogenes and tumor suppressor genes
Necrosis and apoptosis
Charcot-Marie-Tooth disease
Spinal muscular atrophy
Precocious puberty
Delayed puberty
5-alpha-reductase deficiency
Androgen insensitivity syndrome
Kallmann syndrome
Puberty and Tanner staging
Amenorrhea
Hydronephrosis
Beta-thalassemia: Year of the Zebra
Alpha-thalassemia
Beta-thalassemia
Von Willebrand disease
Protein S deficiency
Factor V Leiden
Protein C deficiency
Antithrombin III deficiency
Zellweger spectrum disorders (NORD)
Glycogen metabolism
Hemochromatosis: Clinical sciences
Lesch-Nyhan syndrome
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Adrenoleukodystrophy (NORD)
Alzheimer disease: Clinical sciences
Alzheimer disease

Transcript

Watch video only

With Hypertriglyceridemia, hyper means high, -emia refers to blood levels, and triglycerides are the most abundant fatty molecules in an organism.

So, hypertriglyceridemia is when there’s excess triglycerides in the blood.

Specifically, hypertriglyceridemia is when there are more than 150 mg of triglycerides per deciliter of blood.

Triglycerides can be deposited in subcutaneous tissue and around organs and function as energy storage in the body.

We can either get triglycerides from our diet, which are called exogenous triglycerides; or our liver can synthesize them from other molecules, in which case they’re called endogenous triglycerides.

Now, exogenous triglycerides are first absorbed in the small intestine, and then they undergo a series of changes in order to be transported and deposited in the body.

So, after triglycerides are absorbed, they enter the intestinal mucosal cells, inside of which they’re coupled with various apolipoproteins and phospholipids to create chylomicrons, which are one type of lipoprotein.

Lipoproteins are made up of lipids (like triglycerides or cholesterol) or phospholipids and proteins (like apolipoproteins CII, CIII, or E).

The main job of lipoproteins is to carry insoluble molecules, like triglycerides, from the intestines to the circulation.

That's because, normally, triglycerides are insoluble in liquid environments like blood.

Now, the newly created chylomicrons enter the bloodstream and bind to the wall of capillaries in adipose and skeletal muscle tissue.

At the binding site, they interact with the lipoprotein lipase enzyme leading to the breakdown of the triglyceride core and liberation of free fatty acids directly into the adipocytes or skeletal muscle cell, where they’re either stored or used for energy.

After triglycerides leave the chylomicron, what’s left is called a remnant chylomicron.

Remnant chylomicrons are high in cholesterol esters and they’re cleared from circulation by the liver when the apolipoprotein E binds to Apo-B100/E receptor on the hepatic cell membrane.

The remnant chylomicrons are then degraded by acid hydrolases to a mixture of amino acids, free fatty acids, and cholesterol.

Now let’s switch gears and look at how endogenous triglycerides are synthesized.

First, the liver makes another type of lipoproteins called very low-density lipoproteins, or VLDL.

The fatty acids are either synthesized from scratch from carbohydrates or released from adipose tissue.

Then, the liver exports the triglyceride-rich VLDL molecules into the bloodstream, which carries them to muscle and adipose cells.

Here, VLDL are cleaved by lipoprotein lipase to intermediate-density lipoproteins(IDL), also called VLDL remnants.

The IDL are further metabolized to low-density lipoproteins, LDL, and are released into the bloodstream, which are taken up by the LDL receptor in numerous tissues including the liver.

Ok, so hypertriglyceridemia can result from anomalies in either the exogenous or the endogenous pathways, but in either case, excessive triglyceride levels accumulate in the body.

Depending on where they accumulate, they may cause complications like atherosclerosis and acute pancreatitis.

Now, atherosclerosis can occur via a pathway that involves an endothelial dysfunction.

This dysfunction allows small triglycerides remnants to reach the intimal layer where they get taken up by the macrophages, leading to the formation of foam cells.

Foam cells promote fatty streak formation: the precursor of atherosclerotic plaque.

Acute pancreatitis, on the other hand, occurs due to high concentrations of large chylomicrons in the blood which can obstruct the capillaries leading to ischemia of the pancreas.

Now, hypertriglyceridemia is commonly classified as either primary (or familial) hypertriglyceridemia and secondary (or acquired) hypertriglyceridemia.

Secondary causes are more common, and they may be associated with obesity, diabetes mellitus, high carbohydrate diets, hypothyroidism, or increased alcohol intake, all of which impact lipid metabolism.

Alright, so three of the most common secondary forms of hypertriglyceridemia are obesity, diabetes mellitus type 1 and 2, and high carbohydrate diets.

With obesity-associated hypertriglyceridemia, there is a hepatic overproduction of VLDL and decreased circulating triglycerides breakdown.

On the other hand, in uncontrolled diabetes mellitus, both type 1 and type 2, hypertriglyceridemia is associated with a lipoprotein lipase that is either ineffective or less effective than normal.

Finally, high-carbohydrate diets, where carbohydrates make up more than 60% of the total caloric intake, lead to increased carbohydrate breakdown and increased production of free fatty acids as a consequence.

The excess free fatty acids can be used to synthesize more triglycerides, therefore causing hypertriglyceridemia

Key Takeaways

Hypertriglyceridemia is a condition characterized by high levels of triglycerides in the blood. If individuals' serum triglyceride concentrations are above 150 mg/dL, they are considered hypertriglyceridemia. High levels of triglycerides in the blood are associated with a high risk of developing heart disease, stroke, and other health problems. There are many different causes of hypertriglyceridemia, including genetics, obesity, eating too much processed or unhealthy foods, not getting enough exercise, smoking cigarettes, and drinking alcohol.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Hypertriglyceridemia: its etiology, effects and treatment" Canadian Medical Association Journal (2007)
  7. "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline" The Journal of Clinical Endocrinology & Metabolism (2012)
  8. "Hypertriglyceridemic Pancreatitis: Presentation and Management" The American Journal of Gastroenterology (2009)